LILRB4 and autoimmune disease: [28]. Accordingly, soluble forms of ILT3 are effective inhibitors of T cell proliferation, even in the absence of APC and may be of interest for future therapeutic use as immunomodulators in autoimmune diseases. [6], [12], [28], [29].